FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma

Philippe R.J. Bois, Kamel Izeradjene, Peter J. Houghton, John L. Cleveland, Janet A. Houghton, Gerard C. Grosveld

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Rhabdomyosarcoma (RMS), the most common pediatric soft-tissue sarcoma, has two major histological subtypes: embryonal RMS (ERMS), which has a favorable prognosis, and alveolar RMS (ARMS), which has a poor outcome. Although both forms of RMS express muscle cell-specific markers, only ARMS cells express PAX3-FOXO1a or PAX7-FOXO1a chimeric proteins. In mice, Pax3 and Pax7 play key roles in muscle cell development and differentiation, and FoxO1a regulates myoblast differentiation and fusion; thus, the aberrant regulation of these proteins may contribute to the development of ARMS. In this paper, we report that FOXO1a is not expressed in primary ARMS tumors or ARMS-derived tumor cell lines and that restoration of FOXO1a expression in ARMS cells is sufficient to induce cell cycle arrest and apoptosis. Strikingly, the effects of FOXO1a are selective, as enforced expression of FOXO1a in ERMS-derived tumor cell lines had no effect. Furthermore, FOXO1a induced apoptosis in ARMS by directly activating the transcription of caspase-3 . We conclude that FOXO1a is a potent and specific tumor suppressor in ARMS, suggesting that agents that restore or augment FOXO1a activity may be effective as ARMS therapeutics.

Original languageEnglish (US)
Pages (from-to)903-912
Number of pages10
JournalJournal of Cell Biology
Issue number6
StatePublished - Sep 12 2005
Externally publishedYes

ASJC Scopus subject areas

  • Cell Biology


Dive into the research topics of 'FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma'. Together they form a unique fingerprint.

Cite this